Eli Lilly and Sanofi-backed Scribe surges in public debut
Seeking Alpha ·
Scribe Therapeutics ( SCTX ), a gene therapy developer whose collaborators include Sanofi ( SNY ) and Eli Lilly ( LLY ), rose nearly 50% in its first trading session as a public company on Friday after an upsized IPO that raised
AI 시장 분석
Gene therapy developer Scribe Therapeutics had a successful debut, surging about 50% above its IPO price on its first day of trading. The IPO was achieved through an expanded offering, and news of partnerships with major pharmaceutical companies like Sanofi and Eli Lilly significantly boosted investor sentiment. This indicates a recovery in venture investment and warmth in the IPO market for the biotech sector overall.
상승 영향
- Biotech — Scribe's 50% surge on its first day and partnerships with major pharma are significantly improving investor sentiment in the biotech IPO market.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 57% · Bearish (Short) 43%
242 participants
Related News
- Eastern Bankshares anticipates 2026 net interest income of $1.005B to $1.020B amid deposit competition
- Verizon Stock Jumps as $1B Google AI Deal Sparks Billion-Dollar Growth Outlook
- China Seeks AI Talks Clarity as US Pressure on Chinese AI Intensifies
- Hartford outlines $4.2B buyback plan and targets $475M quarterly repurchases through 2026
- USCB outlines near-term 3.40%-3.50% NIM range while reiterating high single-digit to low double-digit loan growth
- Tesla Sinks 18% in a Month as Lucid Climbs 21%, Rivian Gains 9%: SpaceX Anxiety or Cracks Under the Hood?
